Treatment patterns and real-world evidence for stage III non-small cell lung cancer in Central and Eastern Europe.
Adult
Carcinoma, Non-Small-Cell Lung
/ epidemiology
Consensus
Delphi Technique
Europe
/ epidemiology
Europe, Eastern
/ epidemiology
Evidence-Based Medicine
Female
Humans
Lung Neoplasms
/ epidemiology
Male
Neoplasm Staging
Practice Patterns, Physicians'
/ statistics & numerical data
Surveys and Questionnaires
Delphi method
expert panel
quality of care
real-world evidence
stage III non-small cell lung cancer
treatment patterns
Journal
Radiology and oncology
ISSN: 1581-3207
Titre abrégé: Radiol Oncol
Pays: Poland
ID NLM: 9317213
Informations de publication
Date de publication:
11 10 2020
11 10 2020
Historique:
received:
09
06
2020
accepted:
10
07
2020
pubmed:
14
10
2020
medline:
17
8
2021
entrez:
13
10
2020
Statut:
epublish
Résumé
Background The aim of this project was to collect real-world evidence and describe treatment patterns for stage III non-small cell lung cancer in Central and Eastern Europe. Based on real-world evidence, an expert opinion was developed, and the unmet needs and quality indicators were identified. Patients and methods A systematic literature search and a multidisciplinary expert panel of 10 physicians from 7 countries used a modified Delphi process to identify quality indicators and unmet needs in patients with stage III non-small cell lung cancer. The profound questionnaire was used to characterize treatment patterns used for stage III non-small cell lung cancer, and a systematic review identified patterns in Central and Eastern Europe. The first questionnaire was completed by a group of medical oncologists, radiation oncologists and pneumologists. The panel of experts attended an in-person meeting to review the results of the questionnaire and to process a second round Delphi. An additional survey was then compiled and completed by the panel. Results A complete consensus was reached by the panel of experts on a set of evidence-based clinical recommendations. The experience-based questionnaire generated a highly variable map of treatment patterns within the region. A list of unmet needs and barriers to quality care were developed with near-unanimous consent of the panel of experts. Conclusions The current landscape of diagnostic and therapeutic approaches in Central and Eastern European countries is highly variable. We identified several significant barriers, mainly related to the availability of diagnostic and imaging methods and low rates of chemoradiotherapy with curative intention as initial treatment for unresectable stage III NSCLC.
Identifiants
pubmed: 33048837
doi: 10.2478/raon-2020-0058
pii: /j/raon.ahead-of-print/raon-2020-0058/raon-2020-0058.xml
pmc: PMC7585343
doi:
pii:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
447-454Références
BMC Cancer. 2017 Aug 31;17(1):603
pubmed: 28859609
Oncol Lett. 2017 Nov;14(5):5611-5618
pubmed: 29113190
J Thorac Oncol. 2020 Feb;15(2):288-293
pubmed: 31622733
J Thorac Oncol. 2013 May;8(5):630-6
pubmed: 23584295
Clin Transl Oncol. 2020 May;22(5):759-771
pubmed: 31368078
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Pathol Oncol Res. 2015 Apr;21(2):423-31
pubmed: 25194563
Eur Respir Rev. 2019 Jul 8;28(152):
pubmed: 31285288
Ann Thorac Surg. 2014 Jul;98(1):183-90
pubmed: 24775804
Radiother Oncol. 2011 Feb;98(2):238-43
pubmed: 20951453
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
Lung Cancer. 2020 Jan;139:185-194
pubmed: 31812889
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21
pubmed: 28881918
Radiol Oncol. 2018 Feb 21;52(3):281-288
pubmed: 30210037
Clin Lung Cancer. 2015 Mar;16(2):80-5
pubmed: 25450877
Clin Transl Oncol. 2012 Aug;14(8):613-8
pubmed: 22855143
Clin Transl Oncol. 2019 Nov;21(11):1464-1471
pubmed: 30903517
Chest. 2017 Jan;151(1):193-203
pubmed: 27780786
Clin Transl Oncol. 2011 Jul;13(7):460-71
pubmed: 21775273
Radiol Oncol. 2020 May 28;54(2):209-220
pubmed: 32463394
Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1008-14
pubmed: 20656419
J BUON. 2007 Jan-Mar;12(1):33-9
pubmed: 17436399
Int J Clin Pharm. 2016 Jun;38(3):655-62
pubmed: 26846316